190 related articles for article (PubMed ID: 7707545)
1. Change in tropism upon immune escape by human immunodeficiency virus.
McKnight A; Weiss RA; Shotton C; Takeuchi Y; Hoshino H; Clapham PR
J Virol; 1995 May; 69(5):3167-70. PubMed ID: 7707545
[TBL] [Abstract][Full Text] [Related]
2. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism.
Morikita T; Maeda Y; Fujii S; Matsushita S; Obaru K; Takatsuki K
AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1291-9. PubMed ID: 9339846
[TBL] [Abstract][Full Text] [Related]
3. Structure-function relationships of the HIV-1 envelope V3 loop tropism determinant: evidence for two distinct conformations.
Ebenbichler C; Westervelt P; Carrillo A; Henkel T; Johnson D; Ratner L
AIDS; 1993 May; 7(5):639-46. PubMed ID: 7686374
[TBL] [Abstract][Full Text] [Related]
4. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.
Kato K; Sato H; Takebe Y
J Virol; 1999 Jul; 73(7):5520-6. PubMed ID: 10364300
[TBL] [Abstract][Full Text] [Related]
5. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1.
Inouye P; Cherry E; Hsu M; Zolla-Pazner S; Wainberg MA
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):735-40. PubMed ID: 9643373
[TBL] [Abstract][Full Text] [Related]
7. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
Ly A; Stamatatos L
J Virol; 2000 Aug; 74(15):6769-76. PubMed ID: 10888615
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
[TBL] [Abstract][Full Text] [Related]
9. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
[TBL] [Abstract][Full Text] [Related]
10. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes.
Chesebro B; Wehrly K; Nishio J; Perryman S
J Virol; 1996 Dec; 70(12):9055-9. PubMed ID: 8971043
[TBL] [Abstract][Full Text] [Related]
11. Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope.
Willey RL; Theodore TS; Martin MA
J Virol; 1994 Jul; 68(7):4409-19. PubMed ID: 7515973
[TBL] [Abstract][Full Text] [Related]
12. [Molecular analysis of the principal neutralization epitope (V3 loop) of human immunodeficiency virus type 1 in Argentina].
Gómez Carrillo M; Piccardo C; Libonatti O
Rev Argent Microbiol; 1992; 24(2):91-101. PubMed ID: 1298019
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
[TBL] [Abstract][Full Text] [Related]
14. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
15. Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1.
Harrowe G; Cheng-Mayer C
Virology; 1995 Jul; 210(2):490-4. PubMed ID: 7618285
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG
J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181
[TBL] [Abstract][Full Text] [Related]
17. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.
Schønning K; Jansson B; Olofsson S; Hansen JE
J Gen Virol; 1996 Apr; 77 ( Pt 4)():753-8. PubMed ID: 8627264
[TBL] [Abstract][Full Text] [Related]
18. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
19. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.
Robert-Guroff M; Louie A; Myagkikh M; Michaels F; Kieny MP; White-Scharf ME; Potts B; Grogg D; Reitz MS
J Virol; 1994 Jun; 68(6):3459-66. PubMed ID: 7514675
[TBL] [Abstract][Full Text] [Related]
20. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J
Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
